Elores is a novel patented Antibiotic Adjuvant Entity containing a beta-lactam antibiotic,
a beta-lactamase inhibitor and a non-antibiotic adjuvant.

Mechanism of resistance to antimicrobial agent

  • Impermeability of the drug
  • Alteration in the target molecules
  • Enzymatic drug modification
  • Efflux
  • Biofilm formation

Elores Documentary

Elores Mechanism

Efflux Transporter - Down regulate genes responsible for efflux pump over expression thereby increasing antibiotic sensitivity and combating resistance.

Biofilm - Break and prevents bacterial biofilm increasing antibiotic penetration.

Conjugator - Prevents conjugal transfer thereby improving hospital ecology

Chelates zinc ions in MBLs – thus effective against carbapenem resistant bacteria.

Awarded the Best innovation award – 2013 under India Innovation Growth Program organized by Department of Science & Technology (DST), India, Lockheed Martin, USA, FICCI, India.


  • Lower respiratory tract infections (LRTIs), hospital-acquired and ventilator associated pneumonia (HAP& VAP)
  • Complicated Urinary tract infections (cUTI)

Product Presentation

1.5g/3.0g powder for slow IV administration

Patent Granted

India Patent No. 236996
US Patent No. 8273732
EU Patent No. 1841432



Contact Person

Mr. Saransh Chaudhary
Strategic Board Advisor

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to VRL India, its subsidiaries or affiliates. No use of any VRL India trademark, trade name, or trade dress in this site may be made without the prior written authorization of VRL India, except to identify the product or services of the company.

Back to Top